PARSIPPANY, N.J., Oct. 22, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced the promotion of Gerald R. Melillo, Jr. to president, Sales Services, where he will be responsible for the company's sales operations. Melillo previously served as senior vice president of Business Development and will continue to report to Nancy Lurker, chief executive officer of PDI.
"Since joining our company last year, Gerry's significant experience in pharmaceutical industry sales and marketing has proven to be instrumental in driving PDI's commercial outsource services and contract sales business," stated Lurker. "As a seasoned pharmaceutical executive, we are confident that his results-focused leadership style will continue to create strong shareholder value for our firm. I am delighted to announce his promotion."
Melillo is a biopharmaceutical industry veteran who joined PDI in October 2011. Previously, he was the General Manager for the Southeast Operating Unit for Novartis Pharmaceuticals Corporation, where he was accountable for the operating unit's commercial activities. From 2004 to 2008 at Novartis, he was vice president of the ABGIU Business Franchise, responsible for leading marketing and strategic planning for key in-line brands, multiple brand launches, and key partnerships and joint ventures. Prior to that, he spent 15 years at Pharmacia, Inc. and Upjohn with increasing roles of responsibilities in sales and marketing.
About PDI, Inc.PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.SOURCE PDI, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts